MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

MaxCyte will host a conference call today, March 11, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived ...

(Alliance News) - MaxCyte Inc on Tuesday said its annual loss widened amid higher costs and falling revenue, but it remains optimistic about growth prospects for 2025. The Rockville, Maryland-based ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT) reported fourth quarter ... Adjusted earnings per share came in at -$0.10, better than the -$0.12 analysts expected. MaxCyte’s core business revenue ...

(RTTNews) - MaxCyte, Inc. (MXCT), a cell-engineering ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

MaxCyte (NASDAQ:MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...

MaxCyte Raises Q4 Guidance Driven by SPL Revenue MaxCyte sells electroporation tools and Strategic Platform License (SPLs). The net present value (NPV) of an SPL is $85 million, according to MaxCyte.

ROCKVILLE, MD, March 11, 2025 - MaxCyte, Inc., (NASDAQ: MXCT; LSE ... increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter ...

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform ...